ALB and AIDS: This study aimed to evaluate the predictive value of the serum albumin change rate (Alb Change Rate) for treatment efficacy in patients with AIDS-related non-Hodgkin lymphoma (AR-NHL) undergoing targeted therapy (e.g., rituximab), and to explore the clinical implications of serum albumin (Alb) dynamics during treatment.